Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy -
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA -
Minerva Urol Nephrol. 2021 Aug;73(4):481-488. doi: 10.23736/S2724-6051.20.03662-0. Epub 2020 Feb 19.
To examine the predictive value of neutrophil-to-lymphocyte ratio in localized prostate cancer for surgical pathology and recurrence in patients treated by radical prostatectomy.
We evaluated 1258 patients treated by radical prostatectomy at San Raffaele Hospital between 2011 and 2017 and assessed the association between preoperative neutrophil-to-lymphocyte ratio and surgical pathology (advanced stage, grade group ≥4, nodal involvement, grade discordance between biopsy and surgical pathology) and biochemical recurrence.
The preoperative neutrophil-to-lymphocyte ratio was not significantly associated with advanced stage (≥T3), International Society of Urological Pathology (ISUP) grade (≥4) or discordance. At multivariable analysis, patients with higher neutrophil-to-lymphocyte ratio had lower risk of nodal involvement at final pathology (odds ratio [OR]: 0.77; 95% confidence interval [CI]: 0.64, 0.92; P=0.005). The preoperative level of neutrophil-to-lymphocyte ratio was associated with biochemical recurrence on univariate analysis (OR: 0.81, 95% CI: 0.68, 0.96; P=0.017). Such a relationship was not significant at multivariable analysis adjusting for tumor severity (OR: 0.93, 95% CI: 0.79, 1.09; P=0.4).
Neutrophil-to-lymphocyte ratio does not have clinical utility for the prediction of adverse pathology and biochemical recurrence. Further research should focus on its value for predicting regional lymph node metastasis.
研究中性粒细胞与淋巴细胞比值在接受根治性前列腺切除术治疗的局限性前列腺癌患者的手术病理和复发中的预测价值。
我们评估了 2011 年至 2017 年在圣拉斐尔医院接受根治性前列腺切除术的 1258 例患者,并评估了术前中性粒细胞与淋巴细胞比值与手术病理(晚期、Gleason 评分≥4、淋巴结受累、活检与手术病理之间的分级差异)和生化复发之间的相关性。
术前中性粒细胞与淋巴细胞比值与晚期(≥T3)、国际泌尿病理学会(ISUP)分级(≥4)或分级差异无显著相关性。多变量分析显示,中性粒细胞与淋巴细胞比值较高的患者在最终病理中淋巴结受累的风险较低(比值比 [OR]:0.77;95%置信区间 [CI]:0.64,0.92;P=0.005)。术前中性粒细胞与淋巴细胞比值与单变量分析中的生化复发相关(OR:0.81,95%CI:0.68,0.96;P=0.017)。在调整肿瘤严重程度后进行多变量分析时,这种相关性并不显著(OR:0.93,95%CI:0.79,1.09;P=0.4)。
中性粒细胞与淋巴细胞比值对于预测不良病理和生化复发没有临床意义。进一步的研究应集中在其预测区域淋巴结转移的价值上。